Governor's Initiative Paves Way For Pharmaceutical Joint Venture Between Rafarma Pharmaceuticals And St. Petersburg-Based Pharmsynthez

MOSCOW, Jan. 28, 2014

At meetings initiated by Governor Oleg Korolev of Lipetsk, Management from Rafarma and Pharmsynthez have agreed in principal to commence a 'joint venture production plan', with the potential to substantially increase revenues for both companies. The agreement is contingent upon a satisfactory technical audit of Rafarma's facilities by Pharmsynthez to be conducted next month.

The joint venture production plan calls for various Pharmsynthez pharmaceutical products to be manufactured in Rafarma's facilities, almost doubling capacity and expanding market share accordingly. The Ontological and Antibiotic products to be produced currently have domestic revenues of approximately $250,000,000. While Pharmsynthez has an existing market share of approximately 20%, the joint venture production plan with Rafarma anticipates increasing market share to 35% or more.  

"Rafarma's state-of-the-art facility is a sought-after partner in the rapidly-growing Russian pharmaceutical industry and our expanding portfolio of products continues to draw attention from industry participants and investors alike," stated Rafarma CEO Dave Anderson.

About Rafarma Pharmaceuticals, Inc.

Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of the nation's domestic pharmaceutical industry. Rafarma's mission is to work under the auspices of these aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.

For more information on Rafarma Pharmaceuticals, visit: http://rafarma.com